Search
Novo Nordisk and Valo Health Expand Partnership with $4.6 Billion Investment in Drug Discovery for Cardiovascular and Metabolic Diseases
2025-01-09
Novo Nordisk and the AI-powered biotech firm Valo Health have announced an expanded collaboration, committing $4.6 billion to jointly propel 20 novel drug projects focused on cardiovascular diseases, obesity, and type 2 diabetes. This significant investment aims to expedite the development of innovative therapies for cardiometabolic disorders.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
